Patient With Multiple Myeloma Achieves Complete Remission After Teclistamab

A case study presented at the Society of Hematologic Oncology 2024 Annual Meeting in Houston, Texas, showcased an elderly patient with lambda light chain multiple myeloma who achieved complete remission after receiving teclistamab. The bispecific antibody was administered as a fourth-line treatment 12 years after the patient’s diagnosis.

The patient, an 82-year-old woman, had received several therapies since her diagnosis in July 2011. Initial lab results revealed osteolytic lesions, anemia, and impaired kidney function. She received radiotherapy for symptomatic sacral bone lesions. Melphalan-thalidomide-prednisone was then administered, followed by bortezomib-dexamethasone, which led to a “very good partial response,” according to case study authors.

The disease continued to advance, leading practitioners to initiate lenalidomide and dexamethasone for six cycles. “Lenalidomide was 15 mg given on d1/d21, resulting in a serological stable disease,” the authors wrote. By April 2021, further disease progression resulted in hypercalcemia, renal impairment, anemia, bone pain, and elevated lambda serum free light chains (lambda SFLCs). Thus, a third-line treatment regimen was started, consisting of isatuximab-pomalidomide and dexamethasone with zoledronic acid. According to the case study, practitioners began teclistamab after the patient had progressed on the previous treatment for a total of 29 cycles, resulting in lambda SFLCs of 1,453.54 mg/L.

Teclistamab was administered weekly as a fourth-line therapy beginning in November 2023. Step-up dosing and immunoglobulin supplementation occurred monthly. Subsequently, the patient entered remission. Study authors noted, “No signs of cytokine release syndrome or immune effector cell–associated neurotoxicity syndrome occurred during the initiation or thereafter.”

The case study was authored by researchers out of Saint Louis Hospital in Paris, France, and Auch Hospital in Auch, France.

Reference

Haidar N, Salignon K, Jounblat Y, et al. Complete remission after teclistamab treatment in multiple myeloma: case report. Abstract #MM-160. Presented at the Society of Hematologic Oncology 2024 Annual Meeting; September 4-7, 2024; Houston, Texas.